Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of acute myeloid leukemia (a blood cancer) that has a specific genetic change called IDH1 R132 mutation, either newly diagnosed or that has come back or stopped responding to treatment
- People who received treatment through a special French access program for medicines not yet fully approved, and who started that treatment between 1 January 2017 and 1 August 2023
- People who were treated with a medicine called Ivosidenib, either on its own or combined with other blood cancer medicines (such as azacytidine or venetoclax)
- People who were not already enrolled in a clinical trial for IDH inhibitor medicines at the time of treatment
Who may not be able to join:
- People who have said they do not want to take part in this study
- People who received Ivosidenib as part of another clinical trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pierre PETERLIN, Dr, French Innovative Leukemia Organisation
Phone: +33 (0)5 57 62 31 08
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
characterize the Overall survival (OS) in the both cohort : 1st line and Relapsed/Refractory (R/R)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.